May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Treatment of Choroidal Neosvascularization in Myopic Degeneration With Bevacizumab (Avastin) Appears to Improve Short Term Anatomic and Visual Outcomes When Correlated With Vision and SLO–OCT Imaging
Author Affiliations & Notes
  • J. Dominguez
    New York Eye and Ear Infirmary, New York, NY
    Retina Center,
  • S.C. Lalin
    New York Eye and Ear Infirmary, New York, NY
    Ophthalmology,
  • R.C. Gentile
    New York Eye and Ear Infirmary, New York, NY
    Ophthalmology,
  • P.M. Garcia
    New York Eye and Ear Infirmary, New York, NY
    Ophthalmology,
  • M.E. Van Velthoven
    New York Eye and Ear Infirmary, New York, NY
    Ophthalmology,
  • J.M. Romero
    New York Eye and Ear Infirmary, New York, NY
    Retina Center,
  • R.B. Rosen
    New York Eye and Ear Infirmary, New York, NY
    Retina Center,
  • Footnotes
    Commercial Relationships  J. Dominguez, None; S.C. Lalin, None; R.C. Gentile, None; P.M. Garcia, None; M.E. Van Velthoven, None; J.M. Romero, None; R.B. Rosen, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4288. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Dominguez, S.C. Lalin, R.C. Gentile, P.M. Garcia, M.E. Van Velthoven, J.M. Romero, R.B. Rosen; Treatment of Choroidal Neosvascularization in Myopic Degeneration With Bevacizumab (Avastin) Appears to Improve Short Term Anatomic and Visual Outcomes When Correlated With Vision and SLO–OCT Imaging . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4288.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the efficacy of intravitreal Bevacizumab, an anti–vascular endothelial growth factor (VEGF) monoclonal antibody, in the treatment of patients with myopic degeneration complicated by choroidal neovascularization.

Methods: : Retrospective review of 3 patients with myopic degeneration treated with 1.25mg of intravitreal Bevacizumab for choroidal neovascularization. At presentation, the patients were imaged with flourescein and indocyanine angiography in addition to SLO–OCT imaging. The outcome measures were vision, retinal thickness and the retinal surface contour maps.

Results: : Patient #1 is a 52 year–old woman who presented with decreased vision in the right eye (Va 20/400). Post–injection, the vision improved to 20/60 with the retinal thickness decreasing 18.8% and the retinal surface contour map improving 9% on SLO–OCT imaging. Patient #2 is a 48 year–old man who presented with metamorphopsia and decreased vision in the left eye (count–fingers at 1 foot). Post–injection, the retinal thickness decreased by 49.9% and retinal surface contour map decreased by 32% on SLO–OCT imaging. The patient was then treated with a second intravitreal injection of Bevacizumab as the SLO–OCT image demonstrated residual fluid. The retinal thickness decreased an additional 8% with a corresponding 18.5% improvement in the retinal surface contour map. The visual acuity, however, only improved marginally to count fingers at 3 feet despite the dramatic anatomic improvement probably due to extensive sub–retinal fibrosis. Patient #3 is a 64 year–old man who presented complaining of decreased vision in the left eye with a small sub–foveal hemorrhage. Angiography demonstrated the presence of a choroidal neovascular membrane. Two weeks post–injection, the retinal thickness had decreased 40% with a stable visual acuity.

Conclusions: : The treatment of choroidal neovascularization in patients with myopic degeneration with intravitreal Bevacizumab appears to decrease retinal thickness and improve retinal surface contour maps based SLO–OCT imaging. In addition, patients without extensive scarring may potentially recover functional vision with anti–VEGF treatment.

Keywords: choroid: neovascularization • retinal neovascularization • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×